катехоламинергия核完整性和阿尔茨海默病的病理学,症状和进展
Michael C B David1,2, Magdalena A Kolanko1,2, Thomas D Parker1,2,3
1UK Dementia Research Institute Care Research and Technology Centre, Imperial College London, London, UK.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 30, 2025
概括
阿尔茨海默氏病 (AD) 涉及早期损伤的位置 coeruleus (LC),影响认知和症状. 在AD患者中,LC完整性降低与认知能力下降和疾病进展相关.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 神经成像是一种神经成像.
背景情况:
- 诺拉德仁基基 (LC) 显示了阿尔茨海默氏病 (AD) 的早期病理.
- 腰椎功能障碍与AD症状和疾病进展有关.
- 调查LC和黑色物质 (SN) 完整性对于理解AD至关重要.
研究的目的:
- 为了比较AD患者和健康对照者的LC和SN完整性.
- 为了确定LC/SN完整性和AD的认知/神经精神症状之间的关系.
- 评估LC/SN完整性对认知衰退和AD病理学的预测价值.
主要方法:
- 使用了神经黑色素磁共振成像.
- 包括93名AD参与者和29名对照.
- 分析了反映核完整性的LC和SN对比度.
主要成果:
- 与对照组相比,AD患者的LC完整性降低了.
- 减少LC完整性与AD的全球认知和神经精神症状有关.
- 无论是LC还是SN完整性都预测了更快的认知衰退,并与特定的症状有关.
结论:
- 在AD中,catecholaminergic核的完整性至关重要.
- 腰结核完整性与阿尔茨海默病的症状,病理 (pTau217) 和进展率密切相关.
- 无论LC和SN完整性都独立地影响认知表现和AD的下降.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Role of Neurotransmitters in Memory
2.5K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.5K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K


